Japan Pharmaceutical Companies Zero In On DDP-4 Inhibitor Class Of Diabetes Drugs
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers expect to capitalize on DDP-4 inhibitors, a new class of drugs to treat diabetes with fewer adverse effects